Oral bisphosphonate use and risk of postmenopausal endometrial cancer

Polly A. Newcomb, Michael N. Passarelli, Amanda I. Phipps, Garnet L. Anderson, Jean Wactawski-Wende, Gloria Y F Ho, Mary Jo O'Sullivan, Rowan T. Chlebowski

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

Original languageEnglish (US)
Pages (from-to)1186-1190
Number of pages5
JournalJournal of Clinical Oncology
Volume33
Issue number10
DOIs
StatePublished - Apr 1 2015

Fingerprint

Diphosphonates
Endometrial Neoplasms
Women's Health
Time and Motion Studies
Mouth Neoplasms
Osteoporosis
Uterus
Neoplasms
Body Mass Index
Interviews
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Equipment and Supplies
Health

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Newcomb, P. A., Passarelli, M. N., Phipps, A. I., Anderson, G. L., Wactawski-Wende, J., Ho, G. Y. F., ... Chlebowski, R. T. (2015). Oral bisphosphonate use and risk of postmenopausal endometrial cancer. Journal of Clinical Oncology, 33(10), 1186-1190. https://doi.org/10.1200/JCO.2014.58.6842

Oral bisphosphonate use and risk of postmenopausal endometrial cancer. / Newcomb, Polly A.; Passarelli, Michael N.; Phipps, Amanda I.; Anderson, Garnet L.; Wactawski-Wende, Jean; Ho, Gloria Y F; O'Sullivan, Mary Jo; Chlebowski, Rowan T.

In: Journal of Clinical Oncology, Vol. 33, No. 10, 01.04.2015, p. 1186-1190.

Research output: Contribution to journalArticle

Newcomb, PA, Passarelli, MN, Phipps, AI, Anderson, GL, Wactawski-Wende, J, Ho, GYF, O'Sullivan, MJ & Chlebowski, RT 2015, 'Oral bisphosphonate use and risk of postmenopausal endometrial cancer', Journal of Clinical Oncology, vol. 33, no. 10, pp. 1186-1190. https://doi.org/10.1200/JCO.2014.58.6842
Newcomb PA, Passarelli MN, Phipps AI, Anderson GL, Wactawski-Wende J, Ho GYF et al. Oral bisphosphonate use and risk of postmenopausal endometrial cancer. Journal of Clinical Oncology. 2015 Apr 1;33(10):1186-1190. https://doi.org/10.1200/JCO.2014.58.6842
Newcomb, Polly A. ; Passarelli, Michael N. ; Phipps, Amanda I. ; Anderson, Garnet L. ; Wactawski-Wende, Jean ; Ho, Gloria Y F ; O'Sullivan, Mary Jo ; Chlebowski, Rowan T. / Oral bisphosphonate use and risk of postmenopausal endometrial cancer. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 10. pp. 1186-1190.
@article{940b3aadd06f4e45b73d53f54a9c1869,
title = "Oral bisphosphonate use and risk of postmenopausal endometrial cancer",
abstract = "Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95{\%} CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.",
author = "Newcomb, {Polly A.} and Passarelli, {Michael N.} and Phipps, {Amanda I.} and Anderson, {Garnet L.} and Jean Wactawski-Wende and Ho, {Gloria Y F} and O'Sullivan, {Mary Jo} and Chlebowski, {Rowan T.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1200/JCO.2014.58.6842",
language = "English (US)",
volume = "33",
pages = "1186--1190",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Oral bisphosphonate use and risk of postmenopausal endometrial cancer

AU - Newcomb, Polly A.

AU - Passarelli, Michael N.

AU - Phipps, Amanda I.

AU - Anderson, Garnet L.

AU - Wactawski-Wende, Jean

AU - Ho, Gloria Y F

AU - O'Sullivan, Mary Jo

AU - Chlebowski, Rowan T.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

AB - Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=84927614289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927614289&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.58.6842

DO - 10.1200/JCO.2014.58.6842

M3 - Article

VL - 33

SP - 1186

EP - 1190

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -